Recombinant albumin is genetically engineered and derived from a rice-based expression system. It is a highly purified and completely animal-, virus-, and bacteria-free product that was developed as an alternative to plasma-derived HSA, to which it is structurally equivalent.

Market Analysis and Insights: Global Recombinant Albumin Market
In 2020, the global Recombinant Albumin market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% between 2021 and 2027
Global Recombinant Albumin Scope and Market Size
The global Recombinant Albumin market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Albumin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), byType, and by Application for the period 2016-2027.

Segment by Type
OsrHSA
ScrHSA

Segment by Application
Cell Culture Media
Medical Supplements
Other

By Company
Albumedix
Merck
Ventria (InVitria)
NCPC
Oryzogen
HiMedia

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE